骨髓瘤之家 - 医药资讯

骨髓瘤之家 - 医药资讯 https://www.mmbyh.com/forum.php?mod=forumdisplay&fid=39 Latest 20 threads of 医药资讯 Copyright(C) 骨髓瘤之家 Discuz! Board by Comsenz Inc. Sat, 20 Jun 2026 19:51:56 +0000 60 https://www.mmbyh.com/static/image/common/logo_88_31.gif 骨髓瘤之家 https://www.mmbyh.com/ 双靶点CAR-T和异体“现货型”CAR-T的成绩单 | 2026 EHA https://www.mmbyh.com/forum.php?mod=viewthread&tid=2016 医药资讯之家播报 Mon, 15 Jun 2026 04:57:14 +0000 能通过可穿戴式注射器给药：艾沙妥昔单抗皮下剂型获批 https://www.mmbyh.com/forum.php?mod=viewthread&tid=2014 医药资讯之家播报 Thu, 11 Jun 2026 04:16:41 +0000 两大双抗强强联手，“双打”难搞的髓外骨髓瘤 https://www.mmbyh.com/forum.php?mod=viewthread&tid=2013 医药资讯之家播报 Wed, 10 Jun 2026 05:27:17 +0000 一起认识免疫治疗的“灭火器”：托珠单抗 https://www.mmbyh.com/forum.php?mod=viewthread&tid=2011 医药资讯之家播报 Tue, 09 Jun 2026 05:17:30 +0000 骨髓瘤不认“出身”，规范的初始治疗是活得更久的金钥匙 https://www.mmbyh.com/forum.php?mod=viewthread&tid=2009 医药资讯之家播报 Mon, 08 Jun 2026 07:11:46 +0000 所有患者都达到缓解且MRD阴性，体内CAR-T疗法公布最新数据 https://www.mmbyh.com/forum.php?mod=viewthread&tid=2007 医药资讯之家播报 Fri, 05 Jun 2026 05:04:34 +0000 超6年随访：DVRd方案在没移植的初治骨髓瘤中展现持续疗效 https://www.mmbyh.com/forum.php?mod=viewthread&tid=2005 医药资讯之家播报 Wed, 03 Jun 2026 06:07:07 +0000 无进展生存期8.3个月→18个月，Mezigdomide三期数据挺不错啊 https://www.mmbyh.com/forum.php?mod=viewthread&tid=2002 医药资讯之家播报 Mon, 01 Jun 2026 04:09:23 +0000 “SHR-5421”、口服p300/CBP抑制剂“Inobrodib”开展临床试验 https://www.mmbyh.com/forum.php?mod=viewthread&tid=1999 医药资讯之家播报 Thu, 28 May 2026 03:51:01 +0000 HLX15-SC（CD38单抗）1期临床试验在国内完成首例患者给药 https://www.mmbyh.com/forum.php?mod=viewthread&tid=1998 医药资讯之家播报 Wed, 27 May 2026 03:47:55 +0000 40年真实世界数据告诉你：多发性骨髓瘤的脱落率改善了吗 https://www.mmbyh.com/forum.php?mod=viewthread&tid=1997 医药资讯之家播报 Wed, 27 May 2026 03:44:37 +0000 了解多发性骨髓瘤的ADC药物 https://www.mmbyh.com/forum.php?mod=viewthread&tid=1972 医药资讯 MM资料室 Thu, 07 May 2026 04:08:01 +0000 多发性骨髓瘤BCMA ADC药物「玛贝兰妥单抗」在国内获批上市 https://www.mmbyh.com/forum.php?mod=viewthread&tid=1962 医药资讯之家播报 Fri, 17 Apr 2026 14:55:31 +0000 美齐度胺（Mezigdomide），另一款临床试验阶段的CELMoD类药物 https://www.mmbyh.com/forum.php?mod=viewthread&tid=1925 医药资讯之家播报 Mon, 30 Mar 2026 02:54:33 +0000 首个CELMoD类药物，口服药Iberdomide上市申请在中美都已获受理 https://www.mmbyh.com/forum.php?mod=viewthread&tid=1896 医药资讯之家播报 Mon, 02 Mar 2026 10:01:25 +0000 三抗也开始卷起来了？又一款骨髓瘤药物初步研究结果发布 https://www.mmbyh.com/forum.php?mod=viewthread&tid=1894 医药资讯之家播报 Wed, 25 Feb 2026 12:17:32 +0000 CAR-T相关毒性及其管理 https://www.mmbyh.com/forum.php?mod=viewthread&tid=1887 医药资讯 MM资料室 Tue, 10 Feb 2026 07:40:15 +0000 一线治疗再升级！达雷妥尤单抗四药方案在国内也获批了 https://www.mmbyh.com/forum.php?mod=viewthread&tid=1885 医药资讯之家播报 Fri, 06 Feb 2026 07:02:27 +0000 两则药闻：“四药联合方案”和“三特异性抗体” https://www.mmbyh.com/forum.php?mod=viewthread&tid=1876 医药资讯雨泽 Wed, 28 Jan 2026 13:41:15 +0000 信达生物三抗（GPRC5D/BCMA/CD3）获美国FDA快速通道资格认定 https://www.mmbyh.com/forum.php?mod=viewthread&tid=1875 医药资讯之家播报 Wed, 28 Jan 2026 11:35:19 +0000